Krystal Biotech, Inc. (KRYS) Form 8-K — Nov 2, 2026
Krystal Biotech reported Q3 2026 VYJUVEK global revenue of $127.3 million, up 30% year over year, with net income of $63.1 million ($2.13 basic EPS) and $1.2 billion in cash and investments. Nine-month revenue reached $362.9 million versus $282.0 million in the prior-year period. The Board authorized a share repurchase program of up to $400 million, which the company expects to execute opportunistically over roughly two years, citing confidence in long-term growth and disciplined capital allocation.
Key figures
- Eps
- 2.13
- Revenue
- 127300000
- Guidance
- FY 2026 non-GAAP combined R&D and SG&A expense of $155.0-$165.0 million (excluding stock-based compensation)
- Net Income
- 63068000
- Revenue Yoy
- 30%
- Total Assets
- 1586056000
- Cash Position
- 1200000000
- Kb707 dcr
- 75%
- Kb707 orr
- 31%
- Gross margin
- 94%
- Q3 diluted eps
- 2.05
- Nine month revenue
- 362920000
- Nine month basic eps
- 5.9
- Nine month net income
- 173768000
- Q3 revenue prior year
- 97800000
- Q3 net income prior year
- 79365000
- Kb113 bcc regression rate
- more than 80%
- Reimbursement approvals us
- over 760
- Share repurchase authorization
- 400000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.